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ABSTRACT
Objectives To characterise pregnancy course and
outcomes in women with arrhythmogenic right
ventricular dysplasia/cardiomyopathy (ARVD/C).
Methods From a combined Johns Hopkins/Dutch
ARVD/C registry, we identiﬁed 26 women affected with
ARVD/C (by 2010 Task Force Criteria) during 39
singleton pregnancies >13 weeks (1–4 per woman).
Cardiac symptoms, treatment and episodes of sustained
ventricular arrhythmias (VAs) and heart failure (HF)
≥ Class C were characterised. Obstetric outcomes were
ascertained. Incidence of VA and HF were compared
with rates in the non-pregnant state. Long-term disease
course was compared with 117 childbearing-aged
female patients with ARVD/C who had not experienced
pregnancy with ARVD/C.
Results Treatment during pregnancy (n=39) included
β blockers (n=16), antiarrhythmics (n=6), diuretics
(n=3) and implantable cardioverter deﬁbrillators (ICDs)
(n=28). In ﬁve pregnancies (13%), a single VA
occurred, including two ICD-terminated events.
Arrhythmias occurred disproportionately in probands
without VA history (p=0.045). HF, managed on an
outpatient basis, developed in two pregnancies (5%) in
women with pre-existing overt biventricular or isolated
right ventricular disease. All infants were live-born
without major obstetric complications. Caesarean
sections (n=11, 28%) had obstetric indications, except
one (HF). β Blocker therapy was associated with lower
birth weight (3.1±0.48 kg vs 3.7±0.57 kg; p=0.002).
During follow-up children remained healthy (median
3.4 years), and mothers were without cardiac mortality
or transplant. Neither VA nor HF incidence was
signiﬁcantly increased during pregnancy. ARVD/C
course (mean 6.5±5.6 years) did not differ based on
pregnancy history.
Conclusions While most pregnancies in patients with
ARVD/C were tolerated well, 13% were complicated by
VA and 5% by HF.
INTRODUCTION
Arrhythmogenic right ventricular dysplasia/cardio-
myopathy (ARVD/C) is an inherited cardiomyopathy,
characterised by ﬁbro-fatty replacement of the right
ventricular (RV) myocardium, which predisposes
patients to ventricular arrhythmias (VAs), RV dys-
function and an increased risk of sudden cardiac
death.1 2 Patients typically present in their second to
ﬁfth decade with symptoms associated with VAs.3
Inheritance of ARVD/C is autosomal dominant with
reduced penetrance and marked variable expressiv-
ity.4 5 Consistent with this, ARVD/C is equally
common in men and women, although men have a
somewhat worse disease course.3 5 Mutations, pri-
marily in genes encoding the cardiac desmosome, can
be identiﬁed in up to two-thirds of patients.6
Although ARVD/C is frequently diagnosed in
childbearing-aged women,6 little is known about
pregnancy and ARVD/C. Published data are limited
to one small case series and seven isolated case
reports7–14 describing a total of 13 pregnancies.
Thus, beyond appreciation that there are likely
risks associated with the hemodynamic and hormo-
nal changes of pregnancy,15 little disease-speciﬁc
data exist to guide obstetric care of patients with
ARVD/C. Taking advantage of a combined registry
of American and Dutch patients with ARVD/C, we
therefore developed a study to (1) characterise
pregnancy course and outcomes in women with
ARVD/C, (2) identify women at highest risk for
adverse outcomes during pregnancy and (3)
compare overall disease course of childbearing-aged




The study population was drawn from the Johns
Hopkins and Interuniversity Cardiology Institute of
the Netherlands ARVD/C registries. Both prospect-
ively follow patients with ARVD/C. As shown in
ﬁgure 1 and the online supplementary methods, for
this study we included female registry enrolees who
met diagnostic 2010 Task Force Criteria (TFC)16
while childbearing aged (15–45 years) and for whom
childbearing history (parity) was available.
Twenty-six women were diagnosed with ARVD/C
prior to or during at least one completed pregnancy
and constituted our main study population. The
remaining childbearing-aged patients with ARVD/C
served as a comparison group. All registry enrolees
provided informed consent. The study was approved
by the respective institutional review boards.
ARVD/C characteristics
Demographics, family history and cardiac
characteristics were obtained by examination of
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medical records and patients’ self-report as per registry protocol
(see online supplementary methods). Genotype was derived
from direct sequencing of the desmosomal genes and the PLN
gene through either our research17 18 or commercially available
testing. ARVD/C diagnosis was established when 2010 TFC
were fulﬁlled.
Cardiac events included: (1) sustained VA and (2) onset of
heart failure (HF) ≥ Class C. Sustained VA was a composite
measure of spontaneous sustained ventricular tachycardia (VT),
aborted sudden cardiac death or appropriate implantable cardio-
verter deﬁbrillator (ICD) intervention, as described previously.17
In women with multiple endpoints, the ﬁrst event was consid-
ered the censoring event. Onset of Class C HF was deﬁned
based on modiﬁed guidelines of the American College of
Cardiology/American Heart Association.19
Pregnancy course and outcomes
Cardiac and obstetric course were evaluated for each ARVD/
C-affected pregnancy. Maternal phenotype was assessed at
evaluation preceding pregnancy with ARVD/C, during preg-
nancy and at last follow-up. For this assessment, major struc-
tural RV abnormalities were considered those meeting major
structural TFC based on review of echocardiography, cardiac
MRI and RV angiography. Left ventricular (LV) dysfunction was
deﬁned as LV ejection fraction below 55%. Cardiac treatment
prior to and during each pregnancy was recorded. Each preg-
nancy was evaluated for VA and HF, which were collectively
considered major events. New or worsening ARVD/C-related
symptoms were recorded.
The primary obstetric outcome was the rate of live-born chil-
dren without health issues related to pregnancy and/or delivery.
For each pregnancy, gestational duration, type of delivery, birth
weight, obstetric complications and perinatal health were
evaluated. Maternal and child health at last clinical follow-up
were also assessed.
Comparison of major events in pregnant and non-pregnant
women
Likelihood of VA, HF, cardiac transplant and death at last
follow-up was compared between women who had and had not
experienced pregnancy with ARVD/C. Incidence rates of VA and
HF in the pregnant versus non-pregnant state were also
compared.
Statistical analysis
Categorical variables were reported as frequency (%) and com-
pared between groups by the χ2 or Fisher’s exact test.
Continuous variables were summarised as either mean±SD or
median (IQR) and compared across groups using a t test, or
Mann–Whitney U test as appropriate. Incidence rates of VA and
HF were calculated as number of ﬁrst VA and HF events per
person-year in the pregnant versus non-pregnant state. Mid-P
exact tests were used to compare incidence rates. A p value




The main study population included 26 women (21 American)
who experienced at least one viable pregnancy (>13 weeks)
while affected with ARVD/C. First pregnancies began a median
1.1 years (IQR 0.5–3.8) after diagnosis. Nearly half (12/26,
46%) received genetic counselling prior to at least one preg-
nancy. Table 1 shows clinical characteristics at ﬁrst pregnancy.
Figure 1 Ascertainment of the study population. The study population was drawn from the Johns Hopkins arrhythmogenic right ventricular
dysplasia/cardiomyopathy (ARVD/C) registry (arvd.com) and the Interuniversity Cardiology Institute of the Netherlands ARVD/C registry (*University
Medical Center Utrecht, Academic Medical Center Amsterdam and University Medical Center Groningen enrolees). #Diagnosis was based on
fulﬁlment of the 2010 Task Force Criteria.16 §First-trimester fetal loss excluded.
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Pregnancies
These 26 women experienced 39 singleton pregnancies progres-
sing beyond the ﬁrst trimester (range 1–4, mean age 31.3±3.6)
and 6 clinically recognised ﬁrst trimester losses while affected
with ARVD/C (table 2). The majority (n=29, 74%) of viable
pregnancies began after ARVD/C was clinically recognised and
treated, 7 (18%) began after the patient met TFC but ARVD/C
was not yet clinically recognised and 3 (8%) pregnancies were
ongoing at diagnosis. Sixteen (41%) pregnancies began in the
setting of major structural RV abnormalities (n=7), history of
VA (n=5) or both (n=4) and were considered potentially high
risk. No pregnancy began in the setting of HF. An additional 18
pregnancies (0–4 per woman)—including three miscarriages—
had been completed by these women prior to ARVD/C diagno-
sis without any major cardiac events.
Cardiac management and outcomes of ARVD/C pregnancies
Cardiac and obstetric course and medical management of each
ARVD/C affected pregnancy are described in detail in table 2.
Treatment during pregnancy included β blockers (n=16), antiar-
rhythmics (n=6), diuretics (n=3) and ICDs (n=28). ICDs were
implanted during three pregnancies.
As summarised in ﬁgure 2, most pregnancies (n=32, 82%)
were completed without major cardiac events (VA or HF).
Among these pregnancies, nine involved new or worsening pal-
pitations/premature ventricular complexes (n=7) and/or fatigue/
dyspnoea (n=3). These symptoms were successfully treated via
starting/increasing β blockers (n=3), adding ﬂecainide (n=1) or
short-term use of diuretics (n=1). In four symptomatic pregnan-
cies (case 2—G2P1, case 17, case 24—G2P1 and G4P2), no
medication adjustments were required.
Seven pregnancies were complicated by VA (n=5) or HF
(n=2). As shown in table 3, the likelihood of a major cardiac
event was not signiﬁcantly increased in pregnancies begun in
women with a prior history of VA and/or major structural RV
abnormalities.
Ventricular arrhythmias
A single episode of VA complicated ﬁve pregnancies of ﬁve
women without a prior history of sustained VAs. Interruption of
β blockade was associated with two of these events.
Two VAs were terminated by appropriate ICD interventions.
The ﬁrst was an ICD discharge in the third week of a primigrav-
ida (case 6) who had increasingly frequent non-sustained VT
prepregnancy. The second was a second trimester episode of
anti-tachycardia pacing following a trial β blocker interruption.
With restarted β blocker therapy this woman (case 9) completed
this pregnancy without further VA and had three other unevent-
ful pregnancies maintained on β blockers.
Three women experienced episodes of sustained VT prior to
appropriate clinical recognition of their disease. Case 19 had a
haemodynamically stable VT in week 12 of her second preg-
nancy. She was externally cardioverted, began metoprolol and
received an ICD 3 days later. Case 21 had a haemodynamically
unstable VT in the sixth week of her second pregnancy—
2 weeks after discontinuing metoprolol. VT was terminated by





















1 Yes Yes PKP2 21 Major 0 Minor Major Minor Major
2 Yes Yes PLN 29 0* Minor Minor 0 0 Major
3 Yes Yes PKP2 30 Major Minor Minor Major Minor Major
4 Yes Yes 0 29 0 n/a Minor Major Minor 0
5 Yes Yes 0 23 0 n/a Minor Major Minor Major
6 Yes Yes 0 28 Major n/a 0 Major Minor 0
7 Yes Yes 0 30 Major n/a 0 Major Minor 0
8 Yes Yes 0 28 Major n/a Minor Major Minor 0
9 Yes Yes n/a 27 0 n/a n/a Major Minor Minor
10 Yes No PKP2 19 0 n/a Minor Major Minor Major
11 Yes No PKP2 27 Major n/a Minor 0 Minor Major
12 Yes No PKP2 32 0 n/a 0 Minor Minor Major
13 Yes No PKP2 28 Major n/a 0 Major Minor Major
14 Yes No PKP2 21 Major n/a 0 0 Minor Major
15 Yes No 0 32 0 0 Minor 0 Minor Major
16 Yes No 0 34 0 n/a Minor 0 Minor Major
17 Yes No 0 29 0 n/a 0 Major Minor Major
18 Yes No 0 31 0 n/a Minor Major 0 Major
19 No Yes PKP2 22 n/a n/a 0 Major n/a Major
20 No Yes PKP2 22 0 n/a 0 Major 0 Major
21 No Yes DSP and DSG2 31 n/a n/a Minor Major Minor Major
22 No No PKP2 34 0 n/a 0 Major n/a Major
23 No No PKP2 31 0 n/a 0 Major 0 Major
24 No No PKP2 29 n/a n/a n/a Major Minor Major
25 No Yes PKP2 31 Minor n/a 0 Minor n/a Major
26 No No PKP2 25 Major n/a 0 Major n/a Major
*None.
ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; n/a, not available; TFC, 2010 ARVD/C Task Force Criteria.16
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Table 2 Pregnancy course and outcomes


















1 27 Yes VA+RV
structure
G1P0 Live birth 35 weeks Vaginal No 2 years B, dose *2 Yes Palpitations/
PVCs
No No
30 Yes G2P1 Miscarriage <13 weeks
30 Yes VA+RV
structure





2 30 Yes No G2P1 Live birth Full term Vaginal No 10 years None Yes Fatigue,
palpitations
No No
40 Yes No G3P2 Live birth Full term Vaginal No 12 months Start B in 23rd week Yes PVCs/NSVTs No No
3 37 Yes VA+RV
structure
G1P0 Live birth Full term Vaginal Dysmaturity 2 years B+ diuretics when needed Yes Dyspnoea,
palpitations
No Yes
4 32 Yes VA G1P0 Live birth Full term C-section No 4 years Sotalol No No No No
33 Yes VA G2P1 Live birth Full term C-section No 2 years Sotalol Yes No No No
36 Yes G3P2 Miscarriage <13 weeks
5 29 Yes No G1P0 Live birth 34 weeks C-section Preterm contractions 1 month Sotalol+diuretics≤7 days Yes Mild dyspnoea No No
6 28 Yes RV structure G1P0 Live birth Full term Vaginal Child: scalp laceration
infection due to use of
vacuum
5 years B; change atenolol to
metoprolol
Yes Palpitations Third week: ICD
discharge
No
7 33 Yes VA+RV
structure
G1P0 Live birth Full term C-section No 9 months B Yes No No No
8 28 Yes VA G1P0 Live birth Full term Vaginal No 9 months B Yes No No No
9 29 Yes G1P0 Miscarriage <13 weeks
30 Yes No G2P0 Live birth Full term Vaginal No 4 years B Yes No No No
31 Yes No G3P1 Live birth Full term Vaginal Temporary intrauterine
growth restriction




33 Yes VA G4P2 Live birth Full term Vaginal 23 months B Yes No No No
34 Yes VA G5P3 Live birth Full term Vaginal Meconium-stained
amniotic fluid
3 months B Yes No No No
10 24 Yes No G1P0 Live birth Full term Vaginal No 6 years None (stop B in 4th–8th
week)
Yes No No No
26 Yes No G2P1 Live birth Full term Vaginal Preterm contractions 5 years None (stop B in 4th–8th
week)
Yes No No No
28 Yes No G3P2 Live birth Full term Vaginal No 3 years None (stop B in 4th–8th
week)
Yes No No No
11 31 Yes RV structure G1P0 Live birth Full term C-section No 5 years B; stop valsartan; 22nd
week: + diuretics; 32nd






12 33 Yes No G3P1 Live birth Full term Vaginal No 2 years None Yes No No No
13 30 Yes RV structure G1P0 Live birth Full term C-section Child: hypoglycaemia in
macrosomia
16 years None Yes No No No
34 Yes G2P1 Miscarriage <13 weeks No No
35 Yes RV structure G3P1 Live birth Full term C-section No 11 years None Yes No No No




































27 Yes G2P1 Miscarriage <13 weeks No No
28 Yes RV structure G3P1 Live birth Full term Vaginal No Newborn None Yes No No No
15 32 Yes No G5P2 Live birth Full term Vaginal No 3 years None No No No No
16 34 Yes No G2P1 Live birth Full term Vaginal No 18 months None No No No No
17 32 Yes No G3P2 Live birth Full term Vaginal No 2 years B Yes Palpitations/
PVCs
No No
18 32 Yes No G2P1 Live birth Full term Vaginal No 4 months None No No No No
19 31 No No G1P0 Live birth Full term C-section No 9 years None No No No No
33 No No G2P1 Live birth Full term C-section No 7 years Start B since VA Yes Palpitations 12 weeks: VT No
20 23 No No G2P1 Live birth Full term Vaginal No 9 years None No No No No
21 32 No No G2P1 Live birth Full term C-section No 18 months Stop B in 4th week
→VA→start sotalol
Yes PVCs 6th week: VT
+short VF
No
22 34 No No G3P2 Live birth Full term Vaginal No 6 years None No No No No
23 34 No No G3P2 Live birth Full term C-section No 6 years None No No No No
24 29 No No G2P1 Live birth Full term Vaginal No 22 years None No Palpitations/
PVCs
No No
31 No G3P2 Miscarriage <13 weeks
31 No RV structure G4P2 Live birth Full term Vaginal No 19 years None No Fatigue No No
25 31 No No G1P0 Live birth Full term Vaginal No 3 years Start B since VA Yes No 6 weeks: VT No
32 Yes No G2P1 Live birth Full term Vaginal No 2 years B, dose *2 when needed Yes Palpitations No No
26 25 No No G1P0 Live birth Full term Vaginal Meconium stained
amniotic fluid
5 years None No No No No
*Gravidity–parity: gravidity refers to the number of times a subject has been pregnant including the current pregnancy, parity to the number of times a subject has given birth to a fetus with a gestational age of 24 weeks or more.
ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; B, β blocker; C-section, caesarean section; GP, gravidity–parity; HF, heart failure ≥ Class C19; ICD, implantable cardioverter defibrillator; NSVT, non-sustained ventricular tachycardia; PVC,
premature ventricular complex; RV structure, structural abnormalities of the right ventricle that met major structural 2010 Task Force Criteria16; VA, sustained ventricular arrhythmia or appropriate ICD therapy for a ventricular arrhythmia; VF, ventricular
















cardioversion, sotalol 240 mg daily started and an ICD placed
in week 22. Finally, a sustained VT in the sixth gestational week
was the initial clinical presentation of a primigravida (case 25)
subsequently treated with metoprolol 75 mg daily and ICD
placement.
Overall, VA occurred more frequently in pregnancies of pro-
bands (5/21, 24%) than family members (0/18, 0%; p=0.05).
Surprisingly, probands with no prepregnancy history of VA were
most at risk (5/12 (42%) vs 0/9 (0%) probands with prepreg-
nancy VA; p=0.045).
Heart failure
Two pregnancies of primagravidae were complicated by the
onset of HF. Case 3 had a prepregnancy history of VA, major
structural RV abnormalities and mild tricuspid insufﬁciency. She
presented with dyspnoea and palpitations and was diagnosed
with RV-predominant HF with severe tricuspid insufﬁciency in
the ﬁfth gestational month. She was successfully treated on an
outpatient basis with diuretics and had an uncomplicated full-
term vaginal delivery. During 2 years of follow-up, she was
stable with partially improved tricuspid valve function.
Figure 2 Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) pregnancies affected by major cardiac events stratiﬁed by
prepregnancy cardiac history. A. Most pregnancies were completed without major cardiac events. Heart failure ≥ Class C occurred exclusively in
high-risk pregnancies begun with major structural right ventricular (RV) abnormalities (by 2010 Task Force Criteria16). Ventricular arrhythmias did not
recur during pregnancy. VA, sustained ventricular arrhythmia or appropriate implantable cardioverter deﬁbrillator therapy for a ventricular
arrhythmia. B. Worsening cardiac symptoms occurred in the absence of major cardiac events in 9 pregnancies.
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Case 11 had overt biventricular disease prepregnancy (LVejec-
tion fraction 30%–35%). Following recognition of pregnancy,
she discontinued valsartan and was managed on metoprolol
25 mg daily. She developed dyspnoea, mild lower extremity
oedema and increased fatigue in the ﬁfth month and was
diagnosed with biventricular HF with a decreasing LV ejection
fraction (25%–30%) and mild-to-moderate pulmonary hyper-
tension. Outpatient management was achieved with diuretics
and digoxin. An uncomplicated caesarean section, indicated due
to hemodynamic concerns, was performed at 39 weeks. With
restart of valsartan and continued use of diuretics and digoxin,
she is stable 5 years postpartum with unchanged LV function.
While HF was rare, it occurred in one of two pregnancies
begun in the setting of LV dysfunction. In contrast, 9/10 (90%)
pregnancies begun with major structural disease restricted to the
RV were without HF.
Obstetric outcomes
All viable pregnancies progressing beyond the ﬁrst trimester
resulted in live-born children. Thirty-seven (95%) were delivered
full term, and the other two preterm at 34 and 35 weeks. All were
delivered in hospital. A total of 11 caesarean sections (28%) were
performed: one exclusively for ARVD/C-related reasons (HF), the
remainder for primarily obstetric indications. Minor obstetric
complications (table 2) were noted in seven pregnancies (18%); no
major obstetric complications occurred. As shown in table 3, birth
weight was signiﬁcantly lower (but normal) in pregnancies compli-
cated by a major event (3.0±0.63 kg vs 3.5±0.57 kg no major
events; p=0.047). This may be partly attributable to β blockade as
birth weight was signiﬁcantly lower in women taking β blockers
beyond the eighth week (n=16) (3.1±0.48 kg vs 3.7±0.57 kg;
p=0.002). There were no other differences in obstetric outcomes
associated with major cardiac events during pregnancy. All chil-
dren were alive and well at last follow-up at a median age of
3.4 years (IQR 1.6–6.8).
Association of ARVD/C course with pregnancy history
We explored whether experiencing pregnancy while affected
with ARVD/C was associated with long-term disease course by
comparing women who had pregnancies with ARVD/C with the
remainder of our population of female childbearing-aged
patients. As shown in table 4, at ARVD/C diagnosis there were
no signiﬁcant differences in clinical or demographic character-
istics between women who later became pregnant and those
who did not. After a mean 6.5±5.6 years of follow-up, there
were likewise no signiﬁcant differences in likelihood of having
experienced a sustained VA or HF and no difference in likeli-
hood of major RV structural dysfunction. All patients with
ARVD/C who became pregnant were without cardiac mortality
or transplant at last follow-up with none lost to follow-up. One
woman died 1 year after her last delivery from breast cancer.
Incidence rate of VAs and HF in pregnant and non-pregnant
women
Finally, to test whether incidence of VA and HF was more likely
during pregnancy, we compared incidence rates of both in the
pregnant and non-pregnant state. Among female patients with
ARVD/C aged 15–45 years, the incidence rate of VA was 0.138
(CI 0.10 to 0.18) per non-pregnant person-year versus 0.274
(CI 0.10 to 0.61) per pregnant person-year (p=0.17). For HF,
the observed incidence rates were 0.020 per person-year (CI
0.012 to 0.034) in non-pregnant versus 0.070 per person-year
(CI 0.012 to 0.23) in pregnant state (p=0.16).
DISCUSSION
Main ﬁndings
We investigated cardiac and obstetric outcomes of pregnant
patients with ARVD/C ascertained from two large ARVD/C
registries. Our study has four main ﬁndings. First, the majority
of pregnancies were without major cardiac events. Sustained VA
complicated 13% of pregnancies and HF 5%. Second,
Table 3 Association of major cardiac events during pregnancy with demographic, clinical and obstetric characteristics
Overall (n=39)




event vs noneVA (n=5) HF (n=2)
Maternal characteristics
Age (at conception; mean, years) 31.3±3.6 31.7±1.9 34.4±4.7 31.0±3.7 0.34
Nationality (% American) 31 (79) 5 (100) 1 (50) 25 (78) 1.0
Primigravida (%) 14 (36) 2 (40) 2 (100) 10 (31) 0.23
Proband (%) 21 (54) 5 (100) 1 (50) 15 (47) 0.10
Mutation carrier (%) 25 (64) 3 (60) 2 (100) 20 (63) 0.65
ARVD/C history prepregnancy
Recognised disease (%) 29 (74) 2 (40) 2 (100) 25 (78) 0.34
ICD implanted (%) 25 (64) 2 (40) 2 (100) 21 (66) 0.69
Cardiac characteristics prepregnancy
Sustained VT/ICD shock (%, VA) 9 (23) 0 (0) 1 (50) 8 (25) 1.0
Major structural RV disease by 2010 TFC* (%) 11/37 (30) 1 (20) 2 (100) 8/30 (27)* 0.40
LV ejection fraction <55% (%) 2 (5) 0 (0) 1 (50) 1 (3) 0.33
Heart failure ≥ Class C (%, HF) 0 (0) 0 (0) 0 (0) 0(0) 1.0
Obstetric outcomes
Liveborn (%) 39 (100) 5 (100) 2 (100) 32 (100) 1.0
Delivery (% vaginal) 28 (72) 3 (60) 1 (50) 24 (75) 0.38
Birth weight (mean, kg)† 3.4±0.6 3.0±0.4 2.9±1.3 3.5±0.6† 0.047
Full-term delivery (% ≥37 weeks) 37 (95) 5 (100) 2 (100) 30 (94) 1.0
*RV structure prepregnancy was unavailable in two cases.
†Birth weight was unavailable for one full-term healthy infant.
ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; HF, heart failure ≥ Class C19; ICD, implantable cardioverter defibrillator; LV, left ventricular; RV, right ventricular;
TFC, 2010 Task Force Criteria16; VA, sustained ventricular arrhythmia or appropriate ICD therapy; VT, ventricular tachycardia.
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pregnancies resulted in live-born infants without major obstetric
concerns and all children healthy at last follow-up. Third, at last
follow-up, all pregnant patients with ARVD/C were without
cardiac mortality or transplant and did not differ from other
childbearing-aged patients with ARVD/C. Finally, the likelihood
of experiencing a ﬁrst sustained VA or developing HF was not
signiﬁcantly increased during pregnancy.
Prior reports of pregnancy in patients with ARVD/C
Only 13 pregnancies in patients with ARVD/C have been
described in the literature, in contrast to far more robust popu-
lations for other inherited cardiomyopathies and arrhythmia
syndromes.20 Bauce et al7 reported six Italian patients with
mild-to-moderate ARVD/C who tolerated pregnancy well. Two
authors described cases diagnosed during pregnancy who fol-
lowing ICD implantation and initiation of β blocker therapy
delivered healthy infants.8 9 Güdücu et al10 describe an estab-
lished ARVD/C patient with worsening symptoms during her
second pregnancy due to β blocker interruption. In contrast,
two primigravidae had full-term uncomplicated pregnancies
while maintained on β blockers.11 12 Finally, Iriyama et al13 and
Anouar et al14 each report an uneventful pregnancy with caesar-
ean delivery in an established patient. The results of our study
conﬁrm and signiﬁcantly extend these ﬁndings as we assessed
cardiac and obstetric outcomes of sixfold more pregnancies than
the largest prior report.7
Most ARVD/C pregnancies were without major cardiac
events
We found most pregnancies, including those begun in the
setting of major structural RV abnormalities and/or a history of
sustained VAs, were free from major cardiac events. Isolated epi-
sodes of VA complicated ﬁve pregnancies of probands without
prepregnancy VA history. The occurrence of four of these VAs
in the ﬁrst trimester might be related to an arrhythmogenic
effect of hormonal changes at this time.21 22 Altogether, these
results suggest fairly good arrhythmic outcomes when ARVD/C
is well established and treatment adequate, particularly given the
typical arrhythmic course of ARVD/C.6 HF developed in the
second trimester of two women with pre-existing signiﬁcant
structural disease as hemodynamic load increased. Of note, HF
did not develop in 90% of pregnancies begun with isolated RV
abnormalities.
The reason for this favourable outcome is uncertain. In
patients with ARVD/C, increased hemodynamic stress associated
with exercise promotes arrhythmias and also negatively modiﬁes
cardiac structure.23 In contrast to exercise, the relatively shorter
term and gradually developing nature of hemodynamic load
during pregnancy might limit this process. In animal models,
the myocardial response to volume- or pressure-induced stress is
different in male and female hearts, with preserved ejection frac-
tion and less ﬁbrosis in female models. In addition, the interrela-
tionship between oestrogen and testosterone may contribute to
sex differences in disease manifestation.24 Similar mechanisms
may also be protective in pregnancy.
Favourable obstetric outcomes
The obstetric course of patients with ARVD/C was largely unre-
markable. All pregnancies resulted in healthy children without
major obstetric complications. Both prematurity (6.5% of
American subjects) and birth weights were normal,25 26
although women taking β blockers or experiencing major events
during pregnancy had children with a signiﬁcantly lower birth
weight. First trimester losses represented a normal rate of 13%
of clinically recognised pregnancies.27 Of 11 caesarean sections,
only one was exclusively ARVD/C indicated (HF). The 28%
caesarean-section rate was unremarkable, given the population
rates of 33% in the USA and 17% in the Netherlands.28
No differences in long-term ARVD/C course and incidence of
cardiac events
Among women of childbearing age with ARVD/C, the incidence
rate of VA and HF was not signiﬁcantly elevated during preg-
nancy. All pregnant patients with ARVD/C were without cardiac





diagnosed (n=117) p Value
Demographic characteristics
Proband (%) 83 (58) 13 (50) 70 (60) 0.36
Mutation carrier (%) 95 (67) 16 (64) 79 (68) 0.69
European ancestry 138 (96) 26 (100) 112 (96) 0.59
Clinical characteristics at diagnosis
Age (median, IQR) 30 (21–39) 28 (25–32) 31 (21–41) 0.14
Sustained VT/VF (% VA) 50 (35) 6 (23) 44 (38) 0.16
Heart failure ≥ Class C (%) 2 (1.7) 0 (0) 2 (1.4) 1.0
Major RV structural abnormalities by Task
Force Criteria (n=132)
54/132 (41) 8/25 (32) 46/107 (43) 0.31
Cardiac outcomes at last follow-up
Sustained VT/ICD shock (% VA) 73 (51) 12 (46) 61 (52) 0.58
Heart failure ≥ Class C (%) 16 (11) 2 (8) 14 (12) 0.73
Major RV structural abnormalities (by TFC) 68 (48) 10 (39) 58 (50) 0.31
Transplant 3 (2.1) 0 (0) 3 (2.6) 1.0
Death 4 (3) 1 (4) 3 (3) 0.56
Follow-up duration (mean years from diagnosis) 6.5±5.6 8.2±5.3 6.1±5.6 0.08
*Pregnancy proceeding beyond the first trimester.
ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; ICD, implantable cardioverter defibrillator; RV, right ventricular; TFC, 2010 ARVD/C Task Force Criteria16;
VA, sustained ventricular arrhythmia or appropriate ICD therapy for a ventricular arrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia.
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mortality or transplant at last follow-up. Furthermore, there was
no difference in likelihood of sustained VA or HF at last
follow-up between these mothers and women who had not
experienced pregnancy with ARVD/C. This suggests that preg-
nancy does not lead to a precipitous decline in most women.
Some caution while interpreting these data is warranted as preg-
nancy is, of course, not randomly selected.
Implications for clinical care
Our results suggest most patients with ARVD/C can be managed
successfully through pregnancy and highlight several manage-
ment considerations. Preconception arrhythmia management
should be optimised using drugs with low fetal toxicity. ICD
implantation, if indicated based on prepregnancy risk stratiﬁca-
tion,6 17 should be performed prior to pregnancy.
Preconception assessment of biventricular structure and function
is helpful since HF is more likely in those with structural
abnormalities. LV dysfunction is associated with poor
pregnancy outcomes in women with dilated cardiomyopathy20
and appears likely to be so for patients with ARVD/C as well.
Genetic counselling to discuss the heritable nature of ARVD/C
should be offered. Following recognition of pregnancy,
discontinuation of medication with low fetal risk (eg, β blockers)
is not advised. Vaginal delivery with cardiac monitoring is rea-
sonable in many cases. For uneventful pregnancies, a 3-month
postpartum visit followed by usual cardiac care is recommended
as pregnancy is not expected to worsen long-term disease
course.
Study limitations
Data were obtained from two registries; as such, management
decisions were at the discretion of the treating physician and
hence vary between pregnancies and between subjects. In par-
ticular, variability in evaluation of cardiac structure and function
precluded deﬁnitive analysis of possible structural progression
during pregnancy. While ARVD/C management is similar in
America and the Netherlands,5 6 obstetric care differs substan-
tially which may have inﬂuenced outcomes. However, while
Dutch women have high rates of care by midwives, home-births,
drug-free deliveries and relatively low caesarean section rates,28
the Dutch patients with ARVD/C had medically managed preg-
nancies with hospital deliveries.
Our study included no women with HF diagnosed prepreg-
nancy, a population likely at very high risk. Ascertainment of
subjects through a registry of living patients also creates a selec-
tion bias that may mask catastrophic pregnancy outcomes. With
regard to comparison of long-term outcomes in the overall
population, women obviously self-selected whether to become
pregnant and hence may differ in some systematic way beyond
the data shown in table 4. In particular, a subset of women may
have been advised against pregnancy, but data on medical advice
given regarding childbearing are unavailable.
CONCLUSIONS
We found most pregnancies in women with ARVD/C are toler-
ated well. Even most patients with a prior history of sustained
VAs and isolated RV structural disease had favourable outcomes.
However, β-blocker therapy was associated with lower birth
weight and patients with pre-existing overt biventricular disease
are likely at signiﬁcant risk for developing HF as pregnancy
progresses.
Key messages
What is already known on this subject?
Only 13 pregnancies in women with arrhythmogenic right
ventricular dysplasia/cardiomyopathy have been described in the
literature in one small case series and seven case reports.
What might this study add?
We assess cardiac and obstetric outcomes of 39 pregnancies,
triple the number previously reported. We also compare
incidence of ventricular arrhythmias and heart failure in the
pregnant and non-pregnant state, and long-term outcomes of
childbearing-aged patients with arrhythmogenic right ventricular
dysplasia/cardiomyopathy (ARVD/C) who became pregnant with
those who did not.
How might this impact on clinical practice?
This study signiﬁcantly enhances the evidence base for patients
with ARVD/C considering pregnancy and their physicians. These
results suggest that most pregnancies of patients with ARVD/C
are tolerated well. However, 13% of pregnancies were
complicated by sustained ventricular arrhythmias and 5% by
onset of heart failure.
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